Stevanato Group (NYSE:STVN) Issues Earnings Results

Stevanato Group (NYSE:STVN) issued its earnings results on Thursday. The company reported €0.20 ($0.22) earnings per share for the quarter, hitting analysts’ consensus estimates of €0.20 ($0.22), Zacks reports. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Stevanato Group updated its FY 2025 guidance to 0.544-0.587 EPS.

Stevanato Group Stock Performance

NYSE:STVN traded up €0.99 ($1.06) during trading on Thursday, reaching €20.05 ($21.56). The company’s stock had a trading volume of 367,991 shares, compared to its average volume of 327,520. Stevanato Group has a 12 month low of €16.56 ($17.81) and a 12 month high of €33.49 ($36.01). The firm has a market cap of $6.07 billion, a price-to-earnings ratio of 42.66, a price-to-earnings-growth ratio of 7.18 and a beta of 0.56. The firm has a 50 day moving average of €21.40 and a 200-day moving average of €20.51. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wolfe Research started coverage on Stevanato Group in a research note on Friday, December 13th. They set an “outperform” rating and a $28.00 price target for the company. Bank of America lifted their target price on Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $23.00 price target (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of €28.60 ($30.75).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.